{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-020000","form_type":"8-K","ticker":"RNGE","cik":"0001438943","company_name":"RANGE IMPACT, INC.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.433613+00:00","generated_at":"2026-06-01T22:51:51.099003+00:00","sec_items":["8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Range Impact Q1 2024 revenue rises to $3.9M, net loss widens to $751K","bullets":["Consolidated revenue $3,909,893 in Q1 2024, up 30% YoY from $3,014,887.","Net loss of $751,149 vs $226,860 loss in Q1 2023; gross margin fell from 21.5% to 12.3%.","Consolidated Adjusted EBITDA dropped to $67,034 from $170,961; Range Reclaim segment EBITDA swung to -$318,489.","Range Minerals segment contributed $1,982,115 revenue and $699,267 Adjusted EBITDA in its first quarter.","Graphium Biosciences pre-revenue with $131,640 Adjusted EBITDA loss; company engaged banker for potential divestiture."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-020000","json":"https://secwatch.observer/filing/0001493152-24-020000.json","markdown":"https://secwatch.observer/filing/0001493152-24-020000.md","text":"https://secwatch.observer/filing/0001493152-24-020000.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438943/000149315224020000/0001493152-24-020000-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438943/000149315224020000/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:51:51.099003+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}